Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.

Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease. Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates and CSF Aβ levels in humans. In this annotation, we describe the discovery of 3, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core as well as aspects of its preclinical and Phase 1 clinical characterization.

[1]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[2]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  William Greenlee,et al.  Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. , 2012, Journal of medicinal chemistry.

[4]  Alexander Alex,et al.  Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space , 2011 .

[5]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[6]  Daniel Oehlrich,et al.  The evolution of amidine-based brain penetrant BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[7]  Suresh Babu,et al.  Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.

[8]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[9]  Steven P. Miller,et al.  Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. , 2016, Organic letters.

[10]  Shankar Venkatraman,et al.  Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[11]  K. Nave,et al.  Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles , 2013, The EMBO journal.

[12]  P. Coleman,et al.  Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. , 2007, Bioorganic & medicinal chemistry letters.

[13]  Michael Czarniecki,et al.  Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.

[14]  Matthias Rarey,et al.  Torsion angle preferences in druglike chemical space: a comprehensive guide. , 2013, Journal of medicinal chemistry.

[15]  K. Parris,et al.  Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. , 2015, Journal of medicinal chemistry.

[16]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[17]  B. de Strooper,et al.  BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells , 2013, Proceedings of the National Academy of Sciences.

[18]  Lynn A. Hyde,et al.  Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. , 2016, Journal of medicinal chemistry.

[19]  Marc Wortmann.  Dementia: a global health priority - highlights from an ADI and World Health Organization report , 2012, Alzheimer's Research & Therapy.

[20]  M. Fielden,et al.  Retinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat , 2015, Toxicologic pathology.

[21]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[22]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[23]  J. Macor,et al.  Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists. , 2013, Bioorganic & medicinal chemistry letters.

[24]  David J. Diller,et al.  In Silico hERG Modeling: Challenges and Progress , 2009 .

[25]  D. Theil,et al.  Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice , 2016, Scientific Reports.

[26]  H. Nakanishi,et al.  Cathepsin D Deficiency Induces Lysosomal Storage with Ceroid Lipofuscin in Mouse CNS Neurons , 2000, The Journal of Neuroscience.

[27]  L. Yip,et al.  Synthesis and properties of the sulfonyl analogues of 4(5)-aminoimidazole-5(4)-carboxamide, 4(5)-(formylamino)imidazole-5(4)-carboxamide, guanine, and xanthine. , 1980, Journal of medicinal chemistry.

[28]  N. Ostermann,et al.  Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. , 2006, Journal of molecular biology.

[29]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[30]  D. Roden.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[31]  A. Stamford,et al.  Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. , 2013, Current opinion in chemical biology.

[32]  Lynn A. Hyde,et al.  Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[33]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[34]  A. Lehesjoki,et al.  Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. , 2006, Brain : a journal of neurology.

[35]  Jean-Michel Rondeau,et al.  Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. , 2012, Journal of medicinal chemistry.

[36]  R E Cachau,et al.  Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[38]  Manuel Buttini,et al.  Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.

[39]  J. Klimeš,et al.  Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine , 2014, Expert opinion on drug safety.

[40]  P. Wong,et al.  Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.

[41]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[42]  P. Wong,et al.  Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects , 2014, Journal of neurochemistry.

[43]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[44]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[45]  R. Aebersold,et al.  Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. , 2011, Cell metabolism.

[46]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[47]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[48]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[49]  J. Malmström,et al.  Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity. , 2013, Journal of medicinal chemistry.

[50]  Huadong Tang,et al.  A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING , 2005, Drug Metabolism and Disposition.

[51]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[52]  M. Staufenbiel,et al.  Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. , 2010, Bioorganic & medicinal chemistry letters.

[53]  A. McPhail,et al.  Stereoselective Synthesis of β-Substituted β-Amino Sulfones and Sulfonamides via Addition of Sulfonyl Anions to Chiral N-Sulfinyl Imines , 2006 .

[54]  Ying-zi Xu,et al.  Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) , 2012, Expert opinion on therapeutic patents.

[55]  M. Citron,et al.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[56]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.